10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D raised its position in 10x Genomics, Inc. (NASDAQ:TXG) by 3.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 86,999 shares of the company’s stock after purchasing an additional 2,881 shares during the period. State of New Jersey Common Pension Fund D’s holdings in 10x Genomics were worth $1,964,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its position in shares of 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after acquiring an additional 371 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of 10x Genomics by 451.8% in the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after acquiring an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of 10x Genomics in the third quarter valued at $35,000. First Horizon Advisors Inc. lifted its position in shares of 10x Genomics by 74.1% in the second quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock valued at $37,000 after acquiring an additional 808 shares in the last quarter. Finally, Covestor Ltd lifted its position in shares of 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after acquiring an additional 873 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Justin J. Mcanear sold 2,961 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the sale, the chief financial officer now owns 143,242 shares in the company, valued at $3,227,242.26. This trade represents a 2.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,351 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $98,028.03. Following the transaction, the insider now directly owns 345,704 shares in the company, valued at approximately $7,788,711.12. This represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,061 shares of company stock worth $316,794 in the last 90 days. 10.03% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Citigroup reduced their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, October 30th. Jefferies Financial Group upgraded 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research report on Monday, July 22nd. Canaccord Genuity Group reduced their target price on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, October 10th. Barclays reduced their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, 10x Genomics currently has an average rating of “Moderate Buy” and a consensus target price of $29.19.

10x Genomics Price Performance

10x Genomics stock opened at $13.34 on Monday. The stock’s 50-day moving average is $18.42 and its 200-day moving average is $20.35. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -8.72 and a beta of 1.87. 10x Genomics, Inc. has a 12 month low of $13.30 and a 12 month high of $57.90.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business had revenue of $151.65 million during the quarter, compared to analyst estimates of $158.84 million. During the same quarter last year, the firm earned ($0.51) earnings per share. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. Research analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.